These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21253712)

  • 1. Use of bisphosphonates and risk of breast cancer.
    Vestergaard P; Fischer L; Mele M; Mosekilde L; Christiansen P
    Calcif Tissue Int; 2011 Apr; 88(4):255-62. PubMed ID: 21253712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
    Vestergaard P
    Calcif Tissue Int; 2012 Jan; 90(1):22-9. PubMed ID: 22120197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
    Vestergaard P
    Calcif Tissue Int; 2011 Dec; 89(6):434-41. PubMed ID: 22002678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate.
    Vestergaard P
    Calcif Tissue Int; 2011 Oct; 89(4):265-70. PubMed ID: 21710315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric and esophagus events before and during treatment of osteoporosis.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 Feb; 86(2):110-5. PubMed ID: 19957165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
    Vestergaard P; Schwartz K; Rejnmark L; Mosekilde L; Pinholt EM
    J Oral Maxillofac Surg; 2012 Apr; 70(4):821-9. PubMed ID: 21764202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
    Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
    Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure in patients treated with bisphosphonates.
    Grove EL; Abrahamsen B; Vestergaard P
    J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bisphosphonates and risk of postmenopausal breast cancer.
    Rennert G; Pinchev M; Rennert HS
    J Clin Oncol; 2010 Aug; 28(22):3577-81. PubMed ID: 20567021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R; Blackhouse G; Adachi J
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Osteoporos Int; 2010 Sep; 21(9):1591-7. PubMed ID: 19859641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal and gastric cancer incidence and mortality in alendronate users.
    Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
    J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
    Pazianas M; Clark EM; Eiken PA; Brixen K; Abrahamsen B
    J Bone Miner Res; 2013 Mar; 28(3):455-63. PubMed ID: 23044864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.